Press releases and news
2020
Camurus’ Nomination Committee appointed for the Annual General Meeting 2021
Change in number of shares and votes in Camurus
Camurus’ Interim Report Second Quarter 2020
Camurus has completed a directed share issue of 2 million shares, raising proceeds of SEK 300 million
Camurus intends to carry out a directed share issue of approximately SEK 300 million
Positive results from Phase 2 study of once-weekly FluidCrystal® formulation of setmelanotide in healthy volunteers with obesity
Camurus raises full year 2020 revenue guidance
Braeburn and Camurus enter arbitration proceedings in England
Camurus announces submission of request for final approval of Brixadi™ for the treatment of opioid use disorder in the US
Camurus’ Buvidal® reimbursed in Sweden for the treatment of opioid dependence
Resolutions at the annual general meeting 2020 in Camurus
Camurus’ Interim Report January-March 2020
Camurus Annual Report for 2019
Notice of annual general meeting 2020 in Camurus AB (publ)
Camurus announces strong first quarter demand for Buvidal®
Camurus Full year report 2019
2019
Change in number of shares and votes in Camurus
Camurus has completed a directed share issue of approximately 3.7 million shares, raising proceeds of approximately 300 MSEK
Camurus intends to launch a directed share issue of up to 300 MSEK
Camurus announces new study results showing superior patient reported outcomes with Buvidal® versus standard of care in treatment of opioid dependence
Get the latest news from Camurus
Subscribe to receive latest news from Camurus directly to your email.